Trimetazidine is indicated in prophylactic treatment of episodes of angina pectoris and sequelae of infarction, heart failure. Adjuvant symptomatic treatment of vertigo and tinnitus. Adjuvant treatment of the decline in visual acuity and visual field disturbances presumably of vascular origin.
Dosage & Administration
Angivas 20 Tablet: 1 tablet 3 times daily after meals. Angivas MR Tablet: 1 tablet at mealtimes in the morning and evening. Child: Not recommended. For patients with impaired renal function (creatinine clearance between 15 and 90 mL/min), the starting dose is one tablet twice daily respectively in the morning and in the evening.
This drug is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina, or myocardial infarction. It should not be used in the pre-hospital phase or during the first days of hospitalization. In the event of an angina attack, the coronaropathy should be reevaluated and an adaptation of the treatment considered (drug treatment and possibly revascularisation). In patients with renal failure, prescription of Trimetazidine is not recommended if the creatinine clearance is lower than 15 ml/min (in the absence of specific studies). In patients with severe hepatic failure, in the absence of specific studies, prescription of Trimetazidine is not recommended.